Large employers are beginning to build value-based pricing into purchasing contracts for some specialty drugs, based on plans for 2018 recorded in the latest health benefits survey conducted by the National Business Group on Health.
Released Aug. 8, the survey found 9% of respondents are engaged in outcomes-based or indication-based contracts for specialty drugs, either...